References
1. Church JT, Antunez AG, Dean A, Matusko N, Deatrick KB, Attar MA, et
al. Evidence-based management of chylothorax in infants. J Pediatr
Surg 2017;52:907-912.
2.Buchwald MA, Laasner U, Balmer C, Cannizzaro V, Latal B, Bernet V.
Comparison of postoperative chylothorax in infants and children with
trisomy 21 and without dysmorphic syndrome: Is there a difference in
clinical outcome? J Pediatr Surg 2019;54:1298-1302.
3. Matsukuma E, Aoki Y, Sakai M, Kawamoto N, Watanabe H, Iwagaki S, et
al. Treatment with OK-432 for persistent congenital chylothorax in
newborn infants resistant to octreotide. J Pediatr Surg2009;44:37-39.
4. Vass G, Evans Fry R, Roehr CC. Should Newborns with Refractory
Chylothorax Be Tried on Higher Dose of Octreotide? Neonatology2021;25:1-5.
5. Kim JE, Lee C, Park KI, Park MS, Namgung R, Park IK. Successful
pleurodesis with OK-432 in preterm infants with persistent pleural
effusion. Korean J Pediatr 2012;55:177-180.
6. Cleveland K, Zook D, Harvey K, Woods RK. Massive chylothorax in small
babies. J Pediatr Surg 2009;44:546-550.
7. Takahashi Y, Kinoshita Y, Kobayashi T, Arai Y, Ohyama T, Yokota N, et
al. Management of refractory chylothorax in the neonatal intensive care
unit: A 22-year experience. Pediatr Int 2021; doi:
10.1111/ped.15043.
8. ScottoniF, Fusaro F, Conforti A, Morini F, Bagolan P. Pleurodesis
with povidone-iodine for refractory chylothorax in newborns: Personal
experience and literature review. J Pediatr Surg2015;50:1722-1725.
9. Ono S, Iwai N, Chiba F, Furukawa T, Fumino S. OK-432 therapy for
chylous pleural effusion or ascites associated with lymphatic
malformations. J Pediatr Surg 2010; doi:
10.1016/j.jpedsurg.2010.06.010.
10. Ogita S, Tsuto T, Deguchi E, Tokiwa K, Nagashima M, Iwai N. OK-432
therapy for unresectable lymphangiomas in children. J Pediatr
Surg 1991;26:263-268.